EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

KRAS Inhibition in Pancreatic Ductal Adenocarcinoma

Roshini Pradeep iD, Nooredeen Jamal Isbeih, Freya F Abraham, Ehsan Noori, Zachary P Yeung, Madappa N Kundranda

Journal of Clinical Medicine · 21.01.2026 · 15 (2) · 873

DOI: 10.3390/jcm15020873 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.01.2026. Verfasst von Roshini Pradeep und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, University of Arizona College of Medicine-Phoenix, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS alterations are a hallmark of pancreatic ductal adenocarcinoma (PDAC) found in >90% of tumors. This review examines the historical evolution of the understanding of RAS and its central role in PDAC biology. We summarize the various downstream effectors, feedback loops, and resistance mechanisms that play a pivotal role in PDAC oncogenesis. Our review explores the early development of covalent inhibitors of KRAS G12C and efforts at specific inhibition of other codons and newer approaches of targeted protein degradation. We subsequently summarize the development of panRAS inhibitors and allosteric and switch-region targeting before focusing on rational therapeutic blockade of crosstalk and upstream signaling, with attention to synthetic lethality approaches transitioning from preclinical to early-phase in-human clinical trials. This review elaborates on ongoing KRAS-specific siRNA research and evolving KRAS-directed immunotherapies. We conclude by outlining the current KRAS clinical trial landscape and future areas of investigation.

Schlagwörter

Stichwörter der Autor:innen

KRASKRAS G12C inhibitorRAS mutationcrosstalkpancreatic ductal adenocarcinomaswitch region

Autor:innen und Institutionen

  • Department of Hematology and Oncology, University of Arizona College of Medicine-Phoenix, Banner MD Anderson Cancer Center, Gilbert, AZ 85234, USA.
  • University of Arizona College of Medicine-Phoenix, Phoenix, AZ 85004, USA.

ORCID-Profile: Roshini Pradeep

Zitieren

APA

Pradeep, R., Isbeih, N. J., Abraham, F. F., Noori, E., Yeung, Z. P., & Kundranda, M. N. (2026). KRAS Inhibition in Pancreatic Ductal Adenocarcinoma. Journal of Clinical Medicine, 15(2), 873. https://doi.org/10.3390/jcm15020873

Vancouver

Pradeep R, Isbeih NJ, Abraham FF, Noori E, Yeung ZP, Kundranda MN. KRAS Inhibition in Pancreatic Ductal Adenocarcinoma. Journal of Clinical Medicine. 2026;15(2):873. doi:10.3390/jcm15020873

BibTeX
@article{Pradeep2026,
  author = {Pradeep, Roshini and Isbeih, Nooredeen Jamal and Abraham, Freya F and Noori, Ehsan and Yeung, Zachary P and Kundranda, Madappa N},
  title = {KRAS Inhibition in Pancreatic Ductal Adenocarcinoma},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {873},
  doi = {10.3390/jcm15020873}
}
Kostenlos starten →